Russ Conroy

Results from a pooled case control study indicate that meninges are very radiosensitive in pediatric patients who were treated at prior to age 10 years, supporting reduced dose whole brain irradiation in this population.

A complete response letter from the FDA indicated that poziotinib as a treatment for non-small cell lung cancer harboring HER2 exon 20 insertion mutations cannot be approved in its current form.

Data from the phase 2 CARTIFAN-1 study highlighted a favorable risk-benefit profile for a single infusion of ciltacabtagene autoleucel among patients with relapsed/refractory multiple myeloma.

The appearance of circulating tumor DNA and androgen receptor aberrations yielded lower overall survival rates for patients with metastatic castration-sensitive prostate cancer during the phase 3 TITAN trial, according to Agarwal, MD.

According to Hurvitz, the findings of trials such as DESTINY-Breast04 and TROPiCS-02 shed light on potential new therapies for breast cancer, though more research is needed to address new agents and other unmet needs.

Early results from the phase 1/2 LUPER study indicated that lurbinectedin in combination with pembrolizumab demonstrated no unexpected toxicities and promising preliminary efficacy in the second line for patients with relapsed small cell lung cancer, according to Antonio Calles, MD.

According to an expert, more than 90% of patients with newly diagnosed transplant-ineligible multiple myeloma treated with daratumumab plus lenalidomide and dexamethasone will achieve some type of response.

Income- and race-related disparities concerning supportive therapies for hormone receptor–positive breast cancer require further study to ensure equitable care and access for all patients, according to Melanie Wain Kier, MD, MBA.

The European Commission’s approval of cemiplimab for recurrent or metastatic cervical cancer marks the first second-line immunotherapy option available for this patient population regardless of tumor histology.

Pembrolizumab plus chemotherapy yielded a significant improvement in overall survival compared with placebo plus chemotherapy in patients with HER2-negative advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.

The National Institute for Health and Care Excellence has given a positive opinion of mobocertinib as a treatment for previously treated advanced non-small cell lung cancer with EGFR exon 20 insertion mutations.

Topline results from the phase 2 MIRAGE study indicated that patients with relapsed/refractory indolent B-cell non-Hodgkin lymphoma receiving zandelisib experienced an objective response rate of 75.4%.

Adjuvant capecitabine following concurrent chemoradiotherapy yielded higher failure-free survival rates compared with chemoradiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma.

The European Commission based its approval of zanubrutinib for the management of chronic lymphocytic leukemia on data from the phase 3 SEQUOIA trial and the phase 3 ALPINE trial.

Patients with acute lymphocytic leukemia or lymphoblastic lymphoma can now receive asparaginase erwinia chrysanthemi at 25 mg/m2 on Monday and Wednesday followed by 50 mg/m2 on Friday, or 25 mg/m2 every 48 hours.

Among patients with Philadelphia chromosome–positive acute lymphoblastic leukemia, ponatinib plus chemotherapy yielded higher rates of minimal residual disease–negative complete remission compared with imatinib.

Zolbetuximab and mFOLFOX6 combination therapy demonstrated positive topline efficacy and safety in patients with Claudin 18.2–positive, HER2-negative gastric or gastroesophageal junction adenocarcinoma.

ATG-008 combined with toripalimab produced an objective response rate of 52.4% among patients with relapsed or metastatic cervical cancer in the phase 1/2 TORCH-2 study.

The VENTANA FOLR1 RxDx Assay has received approval from the FDA for identifying epithelial ovarian cancer in patients who may be eligible for treatment with mirvetuximab soravtansine-gynx.

Results from the phase 3 FRUTIGA study indicate that fruquintinib plus paclitaxel produced promising progression-free survival outcomes among patients with second-line gastric cancer, although no significant improvement in overall survival was reported.

In patients with estrogen receptor–positive recurrent endometrial cancer, letrozole and abemaciclib combination therapy produced an objective response rate of 30% and a median progression-free survival of 9.1 months.

Interim data from the phase 1/2 TACTIC-2 trial indicated that treatment with TAC01-HER2 cell therapy produced a 67% disease control rate among a cohort of patients with HER2-positive solid tumors.

Findings from a meta-analysis highlighted an association between risk of cutaneous adverse effects and use of PI3K inhibitors across different types of cancer.

Patients with unresectable stage III non-small cell lung cancer derived the most benefit from durvalumab when combined with either oleclumab or monalizumab vs durvalumab alone.

According to findings from a biomarker analysis of the phase 2 TheraP trial, mean standardized uptake value of PSMA-PET predicted favorable responses to 177Lu-PSMA-617 compared with cabazitaxel in patients with metastatic castration-resistant prostate cancer.

A regimen consisting of personalized therapeutic cancer vaccine, GNOS-PV02, as well as plasmid-encoded IL-12 and pembrolizumab yielded an overall response rate of 20.9% among evaluable patients with unresectable or metastatic hepatocellular carcinoma.

The investigational imaging agent 89ZR-DFO-girentuximab met all primary and secondary end points, exceeding pre-determined sensitivity and specificity targets in clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.

Findings from a randomized phase 3 trial indicated that brentuximab vedotin plus chemotherapy yielded a higher event-free survival rate and lowered the risk of death compared with chemotherapy alone among patients with advanced-stage Hodgkin Lymphoma.

Real-world results from the retrospective SCHOLAR-2 study provided a benchmark for survival in patients with relapsed or recurrent refractory mantle cell lymphoma who received salvage therapy following failure of initial Bruton tyrosine kinase inhibitor therapy.

A conditioning regimen consisting of of Iomab-B prior to a bone marrow transplant met the phase 3 SIERRA trial’s primary end point of durable complete remission compared with conventional care in elderly patients with relapsed or refractory acute myeloid leukemia.